Boston Scientific to Participate in J.P. Morgan Healthcare Conference and Announces Conference Call Discussing Fourth Quarter 2022 Results

MARLBOROUGH, Mass., Jan. 3, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 41^st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 in San Francisco, California. Mike Mahoney, chairman and chief executive officer, will present at approximately 8:15 a.m. PST / 11:15 a.m. EST. Mahoney will be joined by Dan Brennan, executive vice president and chief financial officer, Kenneth Stein, M.D., senior vice president and chief medical officer, Cardiac Rhythm Management, and Lauren Tengler, vice president, Investor Relations, in a question-and-answer session with the host analyst.

On Wednesday February 1, 2023, Boston Scientific will webcast its conference call discussing financial results and business highlights for the fourth quarter ended December 31, 2022. The call will begin at 8:00 a.m. EST, hosted by Mike Mahoney and Dan Brennan. The company will issue a news release announcing financial results for the fourth quarter on February 1 prior to the conference call.

A live webcast and replay for each event will be accessible at investors.bostonscientific.com. The replays will be available beginning approximately one hour following the completion of each event.

About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.  As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.

View original content to download multimedia:https://www.prnewswire.com/news-releases/boston-scientific-to-participate-in-jp-morgan-healthcare-conference-and-announces-conference-call-discussing-fourth-quarter-2022-results-301710457.html

SOURCE Boston Scientific Corporation